Evidence map›Paper›PMID 40279415›Full record

ArticleScience advances2025

MAX inactivation deregulates the MYC network and induces neuroendocrine neoplasia in multiple tissues.

Brian Freie, Ali H Ibrahim, Patrick A Carroll, Roderick T Bronson, Arnaud Augert, David MacPherson, Robert N Eisenman

Abstract read
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Multiple Endocrine Neoplasia Type 5 due to Germline MAX Mutations: A Systematic Review of Tumor Spectrum and Clinical Features.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026
    Pooled it
  2. Review
  3. Review
  4. Article
  5. c-MYC is an aggregation-prone, amyloidogenic protein.bioRxiv : the preprint server for biology · 2026
    Article
  6. MondoA mediates transcriptional coordination between the MYC network and the integrated stress response in pancreatic cancer.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  7. Review
  8. Double jeopardy: howFrontiers in cell and developmental biology · 2026
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Brian FreieBasic Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0003-1450-865X
Ali H IbrahimHuman Biology and Public Health Science Divisions, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0002-9276-0335
Patrick A CarrollBasic Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0001-8147-5750
Roderick T BronsonDivision of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA, USA.
Arnaud AugertHuman Biology and Public Health Science Divisions, Fred Hutchinson Cancer Center, Seattle, WA, USA.
David MacPhersonHuman Biology and Public Health Science Divisions, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0003-3729-907X
Robert N EisenmanBasic Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0002-0274-9846

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4M
The MYC Transcription Factor Network and the Path to CancerR35CA231989 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI EISENMAN, ROBERT NEIL · 2018 to 2024
$6.3M
Investigating Max as a tumor suppressor gene in small cell lung cancer and other neuroendocrine tumorsR01CA248762 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI EISENMAN, ROBERT NEIL, MACPHERSON, DAVID · 2020 to 2024
$2.7M
High-Performance Compute Cluster for Comprehensive Cancer and Infectious Diseases ResearchS10OD028685 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRADLEY, PHILIP · 2020 to 2020
$2.0M
NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA248762NCI NIH HHS R35 CA231989NIH HHS S10 OD028685
6 · The paper itself

Abstract

The MYC transcription factor requires MAX for DNA binding and widespread activation of gene expression in both normal and neoplastic cells. Inactivating mutations in

Indexed as

Basic Helix-Loop-Helix Leucine Zipper Transcription FactorsGene Regulatory NetworksNeuroendocrine TumorsProto-Oncogene Proteins c-mycAnimalsCarcinoma, NeuroendocrineCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMiceTumor Suppressor Protein p53Basic Helix-Loop-Helix Leucine Zipper Transcription FactorsProto-Oncogene Proteins c-mycTumor Suppressor Protein p53

Identifiers

PMID40279415
PMCPMC12024646

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.